Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT2 | O75908 | 1/20 | 0.75 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.75 |
| ▸ | PSMB11 | A5LHX3 | 2/20 | 0.73 |
| ▸ | PSMA7 | O14818 | 2/20 | 0.73 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.73 |
| ▸ | PSMA1 | P25786 | 2/20 | 0.73 |
| ▸ | PSMA2 | P25787 | 2/20 | 0.73 |
| ▸ | PSMA3 | P25788 | 2/20 | 0.73 |
| ▸ | PSMA4 | P25789 | 2/20 | 0.73 |
| ▸ | PSMB8 | P28062 | 2/20 | 0.73 |
| ▸ | PSMB9 | P28065 | 2/20 | 0.73 |
| ▸ | PSMA5 | P28066 | 2/20 | 0.73 |
| ▸ | PSMB4 | P28070 | 2/20 | 0.73 |
| ▸ | PSMB6 | P28072 | 2/20 | 0.73 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.73 |
| ▸ | PSMB10 | P40306 | 2/20 | 0.73 |
| ▸ | PSMB3 | P49720 | 2/20 | 0.73 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.73 |
| ▸ | PSMA6 | P60900 | 2/20 | 0.73 |
| ▸ | PSMA8 | Q8TAA3 | 2/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3448581 | 1.00 | SOAT2 (0.75) | SOAT2SOAT1PSMB11PSMA7PSMB1 | |
| SCHEMBL13109349 | 1.00 | SOAT2 (0.75) | SOAT2SOAT1PSMB11PSMA7PSMB1 | |
| SCHEMBL10581544 | 0.91 | HPGD (0.76) | SOAT2SOAT1PSMB11PSMA7PSMB1 | |
| SCHEMBL16596254 | 0.91 | HPGD (0.76) | SOAT2SOAT1PSMB11PSMA7PSMB1 | |
| SCHEMBL28347915 | 0.91 | HPGD (0.76) | SOAT2SOAT1PSMB11PSMA7PSMB1 | |
| SCHEMBL8671160 | 0.91 | HPGD (0.76) | SOAT2SOAT1PSMB11PSMA7PSMB1 | |
| SCHEMBL11928065 | 0.90 | HPGD (0.78) | SOAT2SOAT1PSMB11PSMA7PSMB1 | |
| SCHEMBL29379899 | 0.86 | SOAT2 (1.00) | SOAT2SOAT1PSMB11PSMA7PSMB1 | |
| Oleic Acid Anilide SCHEMBL4143904 | 0.86 | SOAT2 (1.00) | SOAT2SOAT1PSMB11PSMA7PSMB1 | |
| Oleic Acid Anilide SCHEMBL4143902 | 0.86 | SOAT2 (1.00) | SOAT2SOAT1PSMB11PSMA7PSMB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8907109-B2 | Methods and systems for treating cell proliferation disorders with psoralen derivatives | IMMUNOLIGHT, LLC (US) | 2014-12-09 | — | — | US | disclosed |
| US-8791275-B2 | Methods and systems for treating cell proliferation disorders with psoralen derivatives | DUKE UNIVERSITY (US) | 2014-07-29 | — | — | US | disclosed |
| US-20130129757-A1 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES | IMMUNOLIGHT, LLC (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131429-A1 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES | lmmunolight, LLC (US) | 2013-05-23 | — | — | US | disclosed |
| US-8383836-B2 | Methods and systems for treating cell proliferation disorders with psoralen derivatives | DUKE UNIVERSITY (US) | 2013-02-26 | — | — | US | disclosed |
| WO-2010123996-A1 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES | IMMUNOLIGHT, LLC (US) | 2010-10-28 | — | — | WO | disclosed |
| US-20100266621-A1 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES | DUKE UNIVERSITY (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100266621-A1 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES | CDK20, NFATC1, CDK10 | SOAT2 4214/4885SOAT1 3688/4885PSMB11 1300/4885 |
| US-20130131429-A1 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES | CDK20, NFATC1, CDK10 | SOAT2 4214/4885SOAT1 3688/4885PSMB11 1300/4885 |
| US-20130129757-A1 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES | CDK20, NFATC1, CDK10 | SOAT2 4214/4885SOAT1 3688/4885PSMB11 1300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.